Research chemicalResearch chemicalPsychedelicLysergamide

MiPLA (Lysergic acid methylisopropylamide)

Also known as LAMIDE · Lysergic acid methylisopropylamide

Written by enwyReviewed 15 Jul 20261 sources0 comments

MiPLA (lysergic acid methylisopropylamide, LAMIDE) is a close analogue of LSD in which one ethyl of the diethylamide is replaced with methyl and the other with isopropyl. It is a psychedelic of somewhat lower potency than LSD and has been the subject of a small amount of modern pharmacological research.

01 Overview

MiPLA is structurally very similar to LSD and is thought to share its primary mechanism. It has attracted academic interest as a comparatively "gentle" lysergamide; recent binding and functional studies have profiled it alongside LSD, though it has not been through clinical efficacy trials in patients.

Users report an LSD-like experience that is milder and often shorter, with reduced potency (higher microgram doses are needed). All dose ranges here remain anecdotal, and the standard psychedelic safety considerations apply.

02 Mechanism

Partial agonist at 5-HT2A and related serotonin receptors; the mixed methyl/isopropyl amide reduces potency relative to the diethylamide of LSD.

03 Dosing

Tier	Dose	Route	Notes
Threshold	15–30 mcg	Sublingual	Microdose range.
Common	100–200 mcg	Sublingual	Full psychedelic dose; less potent than LSD.
Strong	200–350 mcg	Oral	Strong experience.

04 Effects

Effect	Magnitude	Evidence
Psychedelic visualsColour and geometric visuals, generally milder than LSD.	5-8 h	Anecdotal
Mood elevationEuphoria and emotional openness with a headspace often called manageable.		Anecdotal
Anxiety at high dosesParanoia or overwhelm possible at strong doses.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
Sympathomimetic effectsRaised heart rate and blood pressure, mydriasis and tremor.	Mild	Common	Anecdotal
Acute psychological distressAnxiety, paranoia or a difficult experience during acute effects.	Moderate	Common	Anecdotal
Persistent perceptual changes (HPPD)Lasting visual disturbances after use.	Moderate	Rare	Observational

06 Legal status

United Kingdom

Class A (Misuse of Drugs Act)

Controlled as a lysergamide. · as of Jan 2026

United States

Possible Schedule I analogue

May be treated as an LSD analogue under the Federal Analogue Act. · as of Jan 2026

07 References

Pharmacological characterisation of LSD analogues including MiPLAPubMed search

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.